Designing A Plug-And-Play System To Produce Engineered Extracellular Vesicles

Extracellular vesicles (EVs) are attracting interest as delivery vehicles because they offer properties that can be difficult to achieve with lipid nanoparticles (LNPs) and viral vectors, including potential immune evasion that supports repeat dosing and tissue-specific tropism. Translating these characteristics into a consistent, scalable platform, however, presents its own challenges. This poster from Lonza researchers describes a modular approach designed to support EV engineering and production while enabling flexibility across therapeutic applications.

Presenting author Vijetha Bhat and co-authors, including Ali Navaei, Marta Venturella, and Davide Zocco, outline a platform built around scaffold-cargo plasmids, post-purification loading, and a dedicated production cell line, Clone 24F11. The poster also explores how this approach supports three oncology programs that have completed Phase 1 studies. Among the findings presented are data on preferential uptake of antisense oligonucleotides (ASOs) by M2 macrophages and STAT6 knockdown, illustrating how the platform is being investigated for targeted delivery and gene modulation. Together, the platform design and program data offer insight into efforts to make EV-based delivery more adaptable and reproducible across therapeutic candidates.

Explore the poster’s data and figures to examine the individual components, understand how they work together, and review the evidence supporting this approach to EV engineering and oncology development.